Phosphorothiolate mRNA Cap Analogs for SMA
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for spinal muscular atrophy (SMA) lack effective compounds, and existing mRNA cap analogs have limitations in stability and translational activity, which hinders their therapeutic potential.
Innovation Solution
Development of novel mRNA 5′-end analogs containing a 5′-phosphorothiolate moiety that inhibit the DcpS enzyme, enhancing mRNA stability and translational efficiency by incorporating a sulfur atom at the 5′-nucleoside position, thereby increasing the expression of SMN proteins and improving gene therapy applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional mRNA cap analogs are used, then mRNA can be synthesized and translated, but the mRNA exhibits low stability and low translational activity under cellular conditions
Solution Approach 1:
The patent applies parameter changes by substituting oxygen atoms with sulfur atoms in the phosphorothiolate moiety of the cap analog structure. This chemical parameter modification creates analogs with altered stability and translational properties, resolving the contradiction between mRNA stability and translational activity through systematic structural variation and optimization
Solution Approach 2:
The invention creates composite cap analog structures combining 7-methylguanosine with phosphorothiolate moieties and various nucleoside components. These composite molecular structures integrate multiple functional elements that collectively provide both enhanced stability and maintained translational activity, overcoming the limitations of conventional single-structure cap analogs
2Reliability
If DcpS enzyme activity is not inhibited, then mRNA degradation can proceed naturally, but therapeutic efficacy in spinal muscular atrophy treatment is insufficient
Solution Approach 1:
The patent implements preliminary anti-action by designing cap analogs that preemptively inhibit DcpS enzyme activity before mRNA degradation can occur. The phosphorothiolate-modified cap structures bind to and block DcpS, preventing the enzyme from catalyzing decapping and subsequent mRNA degradation, thereby extending mRNA half-life and enhancing therapeutic efficacy in SMA treatment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified mRNA cap analogs demonstrate increased resistance to DcpS enzyme activity, leading to enhanced protein biosynthesis and prolonged mRNA half-life, offering promising therapeutic benefits for SMA treatment and gene therapies.
Implementation Method 1
5′-phosphorothiolate cap analogs are used as DcpS enzyme inhibitors which enables their application as a medicine
Implementation Method 2
incorporating a sulfur atom at the 5′-nucleoside position, thereby increasing the expression of SMN proteins
Implementation Method 3
enhancing mRNA stability and translational efficiency by incorporating a sulfur atom at the 5′-nucleoside position
Data Source
AI summary
The present invention relates to nucleotides, analogs of mRNA 5′-end (cap) containing sulfur atom at the position 5′ of 7-methylguanosine nucleoside. The disclosed compounds are recognized (bound and non-hydrolyzed) by DcpS enzyme (Decapping Scavenger), and thus may find therapeutic use as inhibitors thereof. DcpS is cap-specific enzyme with pyrophosphatase activity, which was identified as a therapeutic target in the treatment of spinal muscular atrophy (SMA). Some of the compounds disclosed have additional modifications in the phosphate chain, which modulate their affinity for DcpS enzyme. The present invention also relates to mRNAs modified at the 5′ end with mRNA 5′-end (cap) analogs containing 5′-phosphorothiolate moiety, which mRNAs have an increased stability and translational activity in cellular conditions, to a method of their preparation, their uses, and to a pharmaceutical formulation containing them, wherein L1 and L2 are independently selected from the group comprising O and S, wherein at least one of L1 and L2 is not O.